A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

Tae Yong Kim, Hye Sook Han, Keun Wook Lee, Dae Young Zang, Sun Young Rha, Young Iee Park, Jin Soo Kim, Kyung Hun Lee, Se Hoon Park, Eun Kee Song, Soo A. Jung, Na Mi Lee, Yeul Hong Kim, Jae Yong Cho, Yung Jue Bang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicenter, open-label, phase I/II study determined the maximum tolerated dose (MTD) and evaluated the safety and efficacy of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer (GC). Methods: Patients with HER2-positive GC previously treated with one line of chemotherapy received oral poziotinib (8 mg or 12 mg) once daily for 14 days, followed by 7 days off. Paclitaxel (175 mg/m 2 infusion) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg infusion) were administered concomitantly with poziotinib on day 1 every 3 weeks. Results: In the phase I part, 12 patients were enrolled (7 at dose level 1, 5 at dose level 2). One patient receiving poziotinib 8 mg and 2 receiving poziotinib 12 mg had dose-limiting toxicities (DLTs); all DLTs were grade 4 neutropenia, one with fever. The most common poziotinib-related adverse events were diarrhea, rash, stomatitis, pruritus and loss of appetite. The MTD of poziotinib was determined to be 8 mg/day and this was used in the phase II part which enrolled 32 patients. Two patients (6.3%) had complete responses and 5 (15.6%) had partial responses (objective response rate 21.9%). Median progression-free survival and overall survival were 13.0 weeks (95% CI 9.8–21.9) and 29.5 weeks (95% CI 17.9–59.2), respectively. Conclusions: The MTD of poziotinib combined with paclitaxel and trastuzumab was 8 mg/day. This combination yielded promising anti-tumor efficacy with manageable toxicity in previously treated patients with HER2-positive GC.

Original languageEnglish
JournalGastric Cancer
DOIs
Publication statusPublished - 2019 Jan 1

Keywords

  • Chemotherapy
  • Gastric cancer
  • HER2
  • Poziotinib
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer'. Together they form a unique fingerprint.

  • Cite this

    Kim, T. Y., Han, H. S., Lee, K. W., Zang, D. Y., Rha, S. Y., Park, Y. I., Kim, J. S., Lee, K. H., Park, S. H., Song, E. K., Jung, S. A., Lee, N. M., Kim, Y. H., Cho, J. Y., & Bang, Y. J. (2019). A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-019-00958-4